The novel prostate cancer antigen 3 (PCA3) biomarker

Bourdoumis, Andreas; Papatsoris, Athanasios; Chrisofos, Michael; Efstathiou, Eleni; Skolarikos, Andreas; Deliveliotis, Charalambos

doi:10.1590/s1677-55382010000600003

Cited by 44 publications

(40 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, there is a need for novel prevention and treatment strategies for this disease. Although there are certain clinical prostate cancer diagnostic tests available, such as the measurement of PSA or early prostate cancer antigen-3 levels (11,12), a prediagnostic genetic test is required to screen unsuspected cancers. Accordingly, over the last few decades, scientists have focused on linking SNPs to prostate cancer and several SNPs that substantially affect the risk of prostate cancer were identified (6).…”

Section: Discussionmentioning

confidence: 99%

Risk of prostate cancer and thrombosis-related factor polymorphisms

Ghasemi¹,

Tavakoli²,

Moghadam

et al. 2013

Biomedical Reports

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a complication commonly encountered in cancer patients and is considered to be a major cause of morbidity and mortality. The genetic polymorphisms of thrombophilic factors in cancer patients have been focused on during the last few years. However, the number of available studies on the association between prostate cancer and thromboembolic diseases is limited. Prostate cancer is one of the four major types of cancer and its development is affected by a variety of environmental and genetic factors. In the present study we aimed to focus on the effects of thromboembolic factor gene variations on the risk of prostate cancer. In order to conduct our prospective study, we used amplification-refractory mutation system-polymerase chain reaction to investigate three polymorphisms [factor V Leiden (FVL) G1691A, factor II (prothrombin, PTH) G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T] in prostate cancer patients, via comparison with normal individuals. The results demonstrated no significant differences in FVL and PTH gene variations between cases and controls (P>0.05). Although some cases with the T allele of MTHFR 677 were identified, no significant solidarity was established by statistical analysis (P>0.05). Therefore, non-genetic factors that may disturb homeostatic balance should also be considered in future studies, in order to determine the exact association between VTE and prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk of prostate cancer and thrombosis-related factor polymorphisms

Ghasemi¹,

Tavakoli²,

Moghadam

et al. 2013

Biomedical Reports

View full text Add to dashboard Cite

show abstract

“…It was 1st identified in 1999 due to collaborative research efforts by Johns Hopkins Hospital, Baltimore, and the Radboud University, Nijmegen, Netherland (11), and PCA3 was called differential display clone 3 (DD3). PCA3 is a segment of mRNA from chromosome 9q21-22'segment (12).…”

Section: Prostate Cancer Antigen 3 Genementioning

confidence: 99%

Scrutiny of Prostate Cancer Antigen 3 Effectiveness as an Assist of Prostatic Specific Antigen in Screening and Early Diagnosis of Prostate Cancer: A Review

et al. 2017

View full text Add to dashboard Cite

PSA is the most routine marker to detect prostate cancer, but due to its low specificity that can lead to a number of unnecessary biopsies, there is great need for an alternate method. Can PCA3 be one of these methods? PCA3 is overexpressed in prostate cancer, not in benign conditions such as prostatitis (unlike PSA). Because of its efficacy (being more sensitive and specific in comparison with PSA), this biomarker could be a very useful and promising method for the early detection of prostate cancer, especially in combination with other tests such as TMPRSS2-ERG gene fusion.

show abstract

“…PCA3, a lncRNA that modulates androgen receptor signalling, is highly expressed in prostate cancer cells and is easily detected in body fluids such as blood and urine has already begun to be used as a biomarker in patients with prostate cancer as a tool for determining if repeat prostate biopsies are required (Bourdoumis et al, 2010).…”

Section: Pca3mentioning

confidence: 99%

Long Noncoding RNA s and Cancer

Garzon

Ranganathan

2014

Encyclopedia of Life Sciences

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs), products of pervasive transcription of the human genome, have emerged as important epigenetic regulators of cancer development and progression. LncRNAs, with transcript size ranging from 200 bp to 100 Kb, perform a diverse array of biological roles including chromatin modification, pre‐ and post‐transcriptional regulation, control of cell division, cell‐cycle growth and proliferation and imprinting. They exhibit cell‐specific expression patterns as well as restricted subcellular distribution, and have shown to play a role in multiple cancers such as cancers of the breast, pancreas, liver, lung and colon. Owing to the role they play in cancer initiation and progression, they have emerged as a new class of prognostic indicators, markers of chemotherapy response and finally show promise as targeted therapy against cancer. This article explores the characteristics of lncRNAs, function and association with multiple cancers and highlights the recent progress made on these new molecules especially with respect to cancer. Key Concepts: Long noncoding RNAs are a new class of epigenetic regulatory molecules that are actively transcribed from the human genome. Involved in multiple biological functions including imprinting, transcriptional and post‐transcriptional regulation of gene expression, cell growth, proliferation and differentiation. Dysregulation of lncRNA observed in multiple cancer types, involved in cancer progression and metastasis. LncRNAs can serve as biomarkers, prognostic indicators and predictors of chemotherapy response. Attractive targets for a new group of targeted therapy.

show abstract

The novel prostate cancer antigen 3 (PCA3) biomarker

Cited by 44 publications

References 20 publications

Risk of prostate cancer and thrombosis-related factor polymorphisms

Risk of prostate cancer and thrombosis-related factor polymorphisms

Scrutiny of Prostate Cancer Antigen 3 Effectiveness as an Assist of Prostatic Specific Antigen in Screening and Early Diagnosis of Prostate Cancer: A Review

Long Noncoding RNA s and Cancer

Contact Info

Product

Resources

About